Skip to main content
. Author manuscript; available in PMC: 2012 Aug 1.
Published in final edited form as: Cancer Res. 2011 Jun 13;71(15):5144–5153. doi: 10.1158/0008-5472.CAN-11-0425

Figure 5.

Figure 5

Max and RXRα bind the miR-193a and other promoters and inhibit their expression. A, MAX and B, RXRα occupancy (fold enrichment) at the miR-148a, miR-132, miR-181b, miR-210, miR-193a, miR-148b and miR-335 loci as determined by chromatin immunoprecipitation of ER-Src cells that were or were not treated with TAM. C, miR-193a expression in ER-Src cells treated with tamoxifen for the indicated amount of time in the presence or absence of two siRNAs against MAX and two siRNAs against RXRA or their combination. D, Expression levels of miR-193a primary transcript in non-transformed and transformed ER-Src cells treated with siRNA control or siRNA against Max and/or RXRα. E, Expression of the indicated miRNAs in ER-Src cells treated with tamoxifen for 36h in the presence or absence of siRNAs against MAX, RXRα, or their combination.